3.2 Pathology Interpretation, Histology & Tumor Grading

1.4 Pathology Interpretation, Histology & Tumor Grading

Clinical Blueprint Focus: Deciphering surgical pathology reports is a core competency for advanced practice oncology nurses. The AOCNP exam tests histologic cell lineage classification (carcinoma vs. sarcoma vs. lymphoma), cellular grading systems (Gleason, SBR/Nottingham, FNCLCC), immunohistochemical (IHC) lineage profiles, proliferation markers (Ki-67), and surgical margin status definitions (R0, R1, R2).

---

Histologic Classification & Cell Lineage of Origin

Malignancies are classified based on the embryonic tissue layer and cellular origin from which they arise:

1. Carcinomas (Epithelial Cell Origin): Comprise >80% of adult solid tumors, originating from ectodermal or endodermal epithelial tissue. Subdivided into:
   • Adenocarcinomas: Arise from glandular epithelium (e.g., colon, breast, prostate, lung, pancreas).
   • Squamous Cell Carcinomas: Arise from protective non-glandular stratified squamous epithelium (e.g., head and neck, esophagus, cervix, lung).
   • Urothelial (Transitional Cell) Carcinomas: Arise from the bladder and renal pelvis lining.
2. Sarcomas (Mesenchymal / Connective Tissue Origin): Arise from mesodermal tissues (bone, cartilage, fat, muscle, blood vessels). Subdivided into osteosarcomas, chondrosarcomas, leiomyosarcomas (smooth muscle), liposarcomas (adipose), and angiosarcomas.
3. Hematologic Malignancies (Hematopoietic Origin): Arise from immune and blood-forming elements. Includes Lymphomas (Hodgkin vs. Non-Hodgkin), Leukemias (AML, ALL, CML, CLL), and Multiple Myeloma (plasma cells).
4. Melanomas: Arise from neuroectodermal melanocytes.

---

Histological Tumor Grading Systems

Tumor grade describes the microscopic degree of cellular differentiation, nuclear pleomorphism, and mitotic activity. Unlike stage (which describes anatomical extent), grade reflects intrinsic biological aggressiveness.

General AJCC Grading Scale

• GX: Grade cannot be assessed.
• G1 (Well-Differentiated / Low Grade): Cells closely resemble normal host cells; uniform nuclei; low mitotic rate.
• G2 (Moderately Differentiated / Intermediate Grade): Intermediate structural atypia and mitotic figures.
• G3 (Poorly Differentiated / High Grade): Marked cellular pleomorphism, loss of tissue architecture, high mitotic counts.
• G4 (Undifferentiated / Anaplastic / High Grade): Complete loss of cellular differentiation features; highly aggressive.

Specialty-Specific Grading Systems

• Prostate Cancer (Gleason Score / ISUP Grade Group): Evaluates primary and secondary architectural patterns (scale 1 to 5). Total Gleason score = Primary Pattern + Secondary Pattern (e.g., 3 + 4 = 7). Re-categorized into ISUP Grade Groups 1 (Gleason ≤6) to 5 (Gleason 9–10).
• Breast Cancer (Nottingham / Scarff-Bloom-Richardson System): Evaluates three features (scored 1–3 each): Tubule formation, Nuclear pleomorphism, and Mitotic count. Total score 3–5 = Grade 1; 6–7 = Grade 2; 8–9 = Grade 3.
• Soft Tissue Sarcoma (FNCLCC System): Evaluates Tumor differentiation, Mitotic count, and Tumor necrosis percentage.
• Neuroendocrine Tumors (WHO NET Grading): Graded strictly by Ki-67 proliferation index and mitotic count per 10 high-power fields (HPF):
  • Grade 1: Ki-67 < 3% AND < 2 mitoses/10 HPF.
  • Grade 2: Ki-67 3% to 20% OR 2 to 20 mitoses/10 HPF.
  • Grade 3: Ki-67 > 20% OR > 20 mitoses/10 HPF.

---

Diagnostic Immunohistochemistry (IHC) Panels

Immunohistochemistry uses labeled monoclonal antibodies to identify specific cell-surface and intracellular protein antigens, establishing cell lineage in poorly differentiated tumors or carcinomas of unknown primary (CUP).

CK7 / CK20 Diagnostic Matrix for Unknown Primary

• CK7+ / CK20-: Lung, Breast, Thyroid, Ovary, Endometrium.
• CK7- / CK20+: Colorectal, Merkel cell carcinoma.
• CK7+ / CK20+: Urothelial (bladder), Pancreatic, Gastric.
• CK7- / CK20-: Renal cell, Prostate, Hepatocellular carcinoma.

---

Surgical Resection Margin Status

Pathologic reporting of surgical margins describes the microscopic relationship between neoplastic cells and the inked outer edge of the resected specimen:

Resection Margin Code        Microscopic & Macroscopic Findings         Clinical Impact
---------------------        ----------------------------------         ---------------
R0 Resection                 No tumor cells at the inked margin         Negative margins; optimal local
                             (Microscopically negative).                control achieved.

R1 Resection                 Microscopic tumor cells present at         Microscopic positive margins;
                             the inked surgical margin.                 warrants re-excision or adjuvant
                                                                        radiation therapy.

R2 Resection                 Macroscopic (gross) tumor visible          Gross residual disease left;
                             and remaining in surgical bed.             high local recurrence rate.

Clinical Pearl: Lymphovascular invasion (LVI) and perineural invasion (PNI) documented on a pathology report represent key micro-pathologic risk features. The presence of LVI or PNI indicates higher risk of regional lymph node metastasis and systemic recurrence, often altering adjuvant chemotherapy decisions even in early-stage disease.